CSI Market
Sign In | Register

Travere Therapeutics Inc (TVTX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access TVTX Annual Cash Flow →
The quarterly cash flow data below helps track how Travere Therapeutics Inc's liquidity profile has evolved over recent quarters.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-143.30
Depreciation & amortization29.45
Amortization of Other Assets28.70
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories3.45
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation37.93
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), before Tax, Total-0.95
Cost Of Services-
Costs And Expenses Related Party-
Compensation In Lieu Of Stockholder Receivable-
Share Based Compensation Nonemployees-
Share Based Payment Technology License Contingent Fee-
Increase Decrease In Lease Liability-
Increase Decrease In Settlement Expense-
Bargain Purchase Gain-
Available For Sale Securities Gross Realized Gain Loss Net-
Gain Upon Divestiture Of Assets-
Private Placement Settlement-
Derivative Financial Instruments Warrants Issued Recorded In Interest Expense-
Interest Receivable from Notes Receivable-
Noncash Interest Expense-
Provision Benefit For Inventory-
Change In Lease Assets And Liabilities Net-
In Process Research And Development Expense-
Increase Decrease In Contract With Customer Liability-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.58
Increase (Decrease) in Accounts Payable and Accrued Liabilities-17.21
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities9.19
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets9.46
Other Working Capital4.89
Other Noncash Income (Expense)2.61
Other net0.00
Payments for (Proceeds from) Other Operating Activities53.40
Discontinued operations-0.50
Net Cash flow from Operating Activities17.71
Investing Activities
Capital Expenditures-43.25
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities85.15
Payments to Acquire Marketable Securities-226.64
Real Estate Investments0.00
Payments For Security Deposits For Exclusivity Of Certain Licenses-
Increase In Security Deposit-
Repayment Of Technology License Liability-
Proceeds From Securities Sold Not Yet Purchased-
Paymentsto Security Deposits-
Investment Sold Not Yet Purchased Sale Proceeds-
Payment Of Licensing Agreement Milestone Investing Activities-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-184.74
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-16.27
Long-term debt - borrowings525.00
Long-term debt - repayments-350.89
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock34.93
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-1.05
Proceeds From Advances From Related Parties-
Repayment Of Note Payable Related Party-
Investor Deposit-
Repayment Of Stock Subscription Receivable-
Payment To Investors Participated In August2013 Financing-
Payment Of Acquisition Related Contingent Consideration-
Payment of Other Liability-
Payment Of Guaranteed Minimum Royalty-0.53
Repayment Of Manchester Note Payable-
Proceeds From Credit Agreement-
Proceeds From Note Purchase Agreement-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents93.04
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities191.72
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-25.54
Total Cash Flow24.70
4 historic quarters locked

Sign in to unlock the full Travere Therapeutics Inc cash flow history.

Sign In Create Free Account

About Travere Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001438533-26-000063

Figures are derived from filed reports and may be restated. Historical data is subject to revision.